RLAY - Relay Therapeutics, Inc. Short-Term Debt to Capital
Relay Therapeutics (RLAY) relies on partnerships with tech giants and the pharmaceutical sector to accelerate the discovery of tumor-fighting methods. The company currently operates on investment funds, as commercial products have not yet entered the market. The quotes provided below, where the indicator is 0.00, price in the risk of dependence on third-party laboratories performing drug synthesis and testing.
Summary analytical data breakdowns for relaytx.com (RLAY)
This indicator measures the proportion of liabilities maturing within one year relative to equity, determining short-term financial stability and liquidity risk. For Relay Therapeutics (RLAY), whose cash flow depends on payments from Roche for the Dynamite AI platform, the short-term debt-to-equity ratio serves as a marker of the company's ability to service its debts without compromising the development of oncology drugs.